Camune: Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

Sponsor

University Hospital, Strasbourg, France (Other)

Overall Status

Recruiting

CT.gov ID

NCT05234450

Collaborator

(none)

300

Enrollment

Location

6.9

Anticipated Duration (Months)

43.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this work, the investigators count through the integrated multi-omics analysis to identify different tumor subgroups in pancreatic neuroendocrine tumors and carcinomas regardless of their grade and stage. To achieve this, they will resort to the use of next-generation sequencing approaches (RNAseq, then use of MCP Counter for the absolute quantification of the eight populations of immune cells in the tumor microenvironment), alterations in epigenetics with study of the methylome by MeDIP, ChIPseq, telomere (ALT) study, as well as correlation with peripheral blood neutrophil to lymphocyte ratio and immunohistochemistry data such as Ki67, p53, Rb, DAXX, ATRX, PDL1, immune cell labeling. This will be done on frozen or paraffin material. This work will provide a more complete biological picture of pancreatic neuroendocrine tumors and carcinomas.

Condition or Disease	Intervention/Treatment	Phase
Cancer of Pancreas

Study Design

Study Type:

Observational

Anticipated Enrollment :

300 participants

Observational Model:

Case-Only

Time Perspective:

Prospective

Official Title:

Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

Actual Study Start Date :

Dec 1, 2021

Anticipated Primary Completion Date :

Jun 1, 2022

Anticipated Study Completion Date :

Jun 30, 2022

Outcome Measures

Primary Outcome Measures

Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses [1 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Inclusion criteria:

Adult patient (≥18 years old)
Subject with histologically confirmed tumor or neuroendocrine carcinoma of the pancreas
Subject with tumors or neuroendocrine carcinoma of the pancreas regardless of the stage of the disease
Supported at the University Hospitals of Strasbourg between 01/01/2008 and 01/09/2019
Near therapeutic blood count available (less than 6 months)
Availability of frozen and/or paraffin tumor material
Patients who have already given their consent for their biological resources to be kept at the CRB or in the anatomopathology department of the HUS, and subsequently reused, as well as the anonymous data associated with them, for scientific research purposes.

Exclusion criteria:

Opposition of the patient to participate in the study
Diagnosis other than pancreatic neuroendocrine tumor
Biological tissue from a patient who does not meet all the inclusion criteria
Impossibility of giving informed information to the subject
Patient under judicial protection En savoir plus sur ce texte sourceVous devez indiquer le texte source pour obtenir des informations supplémentaires Envoyer des commentaires Panneaux latéraux